espite the transformative potential of cell and gene therapies, widespread adoption remains limited due to systemic gaps in infrastructure, reimbursement models, and coordination of care.

Gene therapies for rare blood disorders show promise with reduced crises and improved life quality, despite high costs and slow adoption.

CRISPR Therapeutics faces challenges despite FDA approval for a breakthrough therapy, with slow progress impacting stock performance.

Gene therapies are very labor intensive, so despite their life-saving potential, access to and utilization of these therapies is a challenge